Biosynthetic pathways for vaccine production involve using biological systems, such as bacteria, yeast, or mammalian cells, to synthesize components required for vaccine formulations. These pathways allow for the mass production of antigens, proteins, or other biologically active substances that are key ingredients in vaccines. Advances in biotechnology have made it possible to engineer microorganisms or cells to produce large quantities of vaccine components quickly and efficiently. For instance, recombinant DNA technology can be used to introduce genes that code for antigens from a pathogen into a host cell, prompting it to produce the antigen for vaccine use. This method is not only cost-effective but also reduces the need for traditional methods like growing pathogens in culture, ensuring both safety and scalability. Biosynthetic pathways continue to evolve, providing more sustainable, rapid, and flexible options for vaccine production, particularly in response to emerging infectious diseases.
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Post COVID-19 syndrome is associated with sex and severity of first COVID-19 episode in Honduras
Manuel Antonio Sierra Santos, Central American Technological University, Honduras
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Development of a platform UPLC-CAD method for high-throughput lipid quantitation and characterization in novel mRNA LNPs
Janet Muzulu, Sanofi, United States